The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Pfizer will transfer manufacturing tech for Prevenar 13

South Africa's Biovac Institute is getting a big shot in the arm from Pfizer. The U.S. drugmaker has agreed to transfer to the public-private group the technology necessary for it to produce Pfizer's best-selling vaccine, Prevenar 13.

Allergan delivers 'decent' Q3 sales growth, with price hikes driving half of it

All eyes are on Allergan's friendly deal talks with Pfizer, which is anxious to scoop up an acquisition and complete a tax inversion. But with the Irish drugmaker's execs mum on the possible combo Wednesday, the conversation turned to new product launches, drug pricing, and Q3 financials that looked "pretty good."

Merck KGaA and Pfizer play catch-up in lung cancer with a Phase III immuno-oncology trial

Partners Merck KGaA and Pfizer are looking to prove their 5th-place immuno-oncology treatment can contend with the leaders in the field, launching a late-stage lung cancer study to establish the antibody's promise.

Pfizer launches first Prevnar TV spot to bring in the 50-plus crowd

Pfizer knows adults generally don't think they're at risk for pneumococcal pneumonia. So to get them to listen up about pneumonia-blocker Prevnar 13, it linked the disease to those they do take seriously.

Bristol-Myers Q3 ad spending pushes up to $193M on renewed promotions push

For the first time since 2013, Bristol-Myers Squibb reported a year-over-year quarterly ad spending increase. Advertising and product promotion costs rose 13% to $193 million, following two quarters of double-digit decreases this year--and a 14% overall decrease for all of 2014. The last time ad spending was up year over year was 2013's fourth quarter.

Pfizer teams up with the Biovac Institute to produce Prevenar 13 in South Africa

In South Africa, 40% of the national budget for vaccines is used to import Pfizer's Prevenar 13, according to Science and Technology Minister Naledi Pandor. To ease this burden, Pfizer and South Africa's Biovac Institute are entering a 5-year partnership to produce the vaccine domestically, Reuters reported.

Pfizer flirted with a GSK megabid but got rejected: FT

Pfizer admits it's wooing Allergan for a merger worth more than $100 billion. But what it's not saying publicly is that GlaxoSmithKline has rejected its advances. That's the word from the Financial Times, whose sources say Pfizer had been flirting with a GSK buy, but the U.K.-based drugmaker wasn't impressed. Pfizer duly backed away.

Pfizer's sickle cell anemia candidate enters trials, to the delight of delivery partner Halozyme

The first subject in a Phase I study of Pfizer's subcutaneous sickle cell anemia candidate has been dosed, triggering $1 million milestone payment to Halozyme, developer of the enhanze drug delivery platform.

Everybody's talking about the Pfizer-Allergan courtship. Here's the juiciest chatter we've heard

The deal of the year could be arranged by Thanksgiving, or so goes the story. Despite opposition from politicians, despite the tricky nature of pulling off a tax inversion that size, Pfizer and Allergan may well be engaged before the month is out, giving Pfizer its long-sought tax reduction and its answer to the who-will-you-buy question that's popped up on every earnings call since AstraZeneca's final rejection last year.

FDA cites Pfizer for shortfalls at Chinese manufacturing plant

The FDA and European regulators, which have long had concerns about the quality of drugs being manufactured by Chinese companies, are now finding issues at some Chinese plants owned by Big Pharma. The FDA has cited a Pfizer plant in China, while U.K. regulators recently found shortcomings at a GlaxoSmithKline plant there.